The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.
 
Mengzhao Wang
No Relationships to Disclose
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Genentech; Gilead Sciences; Janssen; Nuvalent, Inc.; Regeneron
Research Funding - AstraZeneca (Inst); Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Janssen
 
Ying Hu
No Relationships to Disclose
 
Peng Chen
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Jie Hu
No Relationships to Disclose
 
Xinmin Yu
Research Funding - BeiGene; BMS; Hansoh; Innovent Biologics; MSD
 
Wenhua Liang
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Ligang Xing
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Bo Gao
Consulting or Advisory Role - BeiGene; IMPAC Medical Systems; IMPAC Medical Systems; MSD
 
Yongchang Zhang
No Relationships to Disclose
 
Steven Kao
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; MSD; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; MSD; Pfizer; Roche
 
Yu Yao
No Relationships to Disclose
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Hui Wang
Employment - Dizal Pharma
 
Catherine Shu
Consulting or Advisory Role - AstraZeneca; EMD Serono; Genentech/Roche; Janssen
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche